About the Company
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BBI News
QuickLogic Stock (NASDAQ:QUIK), Quotes and News Summary
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and $2 price target.
Coinbase Cost Cuts, Netflix Earnings And Factor Investing: Forbes AI Newsletter - July 23rd
The company’s EPS numbers have grown by 8.43% over the past 12 months. Brickell Biotech Inc (BBI) – The pharmaceutical company is a Top Short for next week with our AI rating them an F in our ...
Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come
A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca ...
PRTG Portage Biotech Inc.
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment ...
How Cuba Recruits Spies to Penetrate Inner Circles of the U.S. Government
MIAMI—Manuel Rocha was on alert, zigzagging through Miami’s Brickell district, en route to a clandestine meeting—at a church. The retired U.S. ambassador was fearful of being tailed.
Noile-Immune Biotech Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Oncolytics Biotech Inc.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of ...
Pharmala Biotech Holdings Inc MDMA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Krystal Biotech, Inc. (KRYS)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Q4 2023 Krystal Biotech Inc Earnings Call
Krish Krishnan; Chairman & CEO; Krystal Biotech, Inc. Suma Krishnan; President of Research & Development; Krystal Biotech, Inc. Kate Romano; Executive VP & CAO ...
Susan Brickell
Susan Brickell is a senior e-commerce editor at Meredith, covering products in the form of reviews, roundups, and gift guides. She's been a market editor and writer for nearly a decade with her ...
Oncolytics Biotech Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...